AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11682440
Drug: L-NMMA (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (16 micromol min(‐1))
Trial: 11682440
Drug: L-NMMA (64
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (64 micromol min(‐1))
Trial: 9702445
Drug: Lisinopril (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (average of 15 mg daily)
Trial: 8081665
Drug: methylprednisolone (MP)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: methylprednisolone (MP) treatment
Trial: 2644918
Drug: Exercise program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise program (details on dosage and duration not specified)
Trial: 31778442
Drug: Liposomal lidocaine/prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal lidocaine/prilocaine gel
Trial: 25259546
Drug: Valsartan 320
RxNorm normalized name: valsartan 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 320 mg a.m.
Trial: 25259546
Drug: Valsartan 320
RxNorm normalized name: valsartan 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 320 mg p.m.
Trial: 25259546
Drug: Lisinopril 40
RxNorm normalized name: lisinopril 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 40 mg a.m.
Trial: 23596347
Drug: Sublingual fentanyl
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual fentanyl wafer
Trial: 12637196
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D(3) 600 IU daily
Trial: 3544640
Drug: Aminophylline (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (4.5 mg/kg)
Trial: 3544640
Drug: Enprofylline (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprofylline (1.5 mg/kg)
Trial: 26797633
Drug: L-theanine-based nutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-theanine-based nutrient drink
Trial: 23357971
Drug: Gemcitabine (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (dose >17,000 mg/m)
Trial: 23357971
Drug: Gemcitabine (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (dose >15,000 mg/m)
Trial: 20001434
Drug: Tadalafil 40
RxNorm normalized name: tadalafil 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 40 mg once daily
Trial: 17284745
Drug: High-folate diet
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-folate diet with 369 mug food folate/d and a placebo capsule (Group A)
Trial: 17284745
Drug: Low-folate diet
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-folate diet with 73 microg food folate/d and folic acid capsules (Group B, 92 microg folic acid/d)
Trial: 17284745
Drug: Low-folate diet
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-folate diet with 73 microg food folate/d and folic acid capsules (Group C, 191 microg folic acid/d)
Trial: 17284745
Drug: Low-folate diet
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-folate diet with 73 microg food folate/d and folic acid capsules (Group D, 289 microg folic acid/d)
Trial: 14748940
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin C (500 mg/d)
Trial: 14748940
Drug: Low-dose vitamin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vitamin C (50 mg/d)
Trial: 10209562
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) at doses of 0.05, 0.10, or 0.20 lU/kg/day
Trial: 7933500
Drug: Inhalation anesthetics
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation anesthetics (sevoflurane, isoflurane, halothane) with oxygen and nitrous oxide
Trial: 7933500
Drug: Postoperative analgesics
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative analgesics (diclofenac, acetaminophen suppositories, intravenous pentazocine)
Trial: 3124046
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir daily for one year
Trial: 3124046
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir during outbreaks of herpes
Trial: 27714799
Drug: Stand-alone prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stand-alone prescription drug plan (PDP)
Trial: 27714799
Drug: Medicare Advantage
RxNorm normalized name: Advantage Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicare Advantage plan with prescription drug coverage (MA-PD)
Trial: 23948440
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral multivitamin supplementation (vitamin B complex, C and E) for 24 months
Trial: 21125461
Drug: Clazosentan 1
RxNorm normalized name: clazosentan
DrugBank: Clazosentan (DB06677)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Clazosentan 1 mg/h
Trial: 18196636
Drug: Thyroliberin 500
RxNorm normalized name: Thyroliberin
DrugBank: Protirelin (DB09421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thyroliberin 500 mcg twice a day for 5 days
Trial: 14730113
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (25 mg of Zn2+ once daily)
Trial: 1438004
Drug: Flurbiprofen in
RxNorm normalized name: Product containing flurbiprofen in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen in the fed state (with water 15 min after 330 ml of apple juice)
Trial: 4084483
Drug: Bromocriptine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine with prior metoclopramide treatment
Trial: 29533491
Drug: High-dose hemoporfin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose hemoporfin (5 mg/kg)
Trial: 29533491
Drug: Low-dose hemoporfin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose hemoporfin (2.5 mg/kg)
Trial: 27501207
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with routine antiemetic therapy only
Trial: 23283457
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy of dapsone and rifampicin
Trial: 18341562
Drug: Xylitol lozenges
RxNorm normalized name: xylitol Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol lozenges (2.5 g xylitol, 3 times a day)
Trial: 18341562
Drug: Xylitol/fluoride lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol/fluoride lozenges (1.5 mg fluoride, 3 times a day)
Trial: 18341562
Drug: Reference no-tablet
RxNorm normalized name: caffeine Oral Tablet [No Doz]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference no-tablet group (n = 70)
Trial: 12215081
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (MMTP only)
Trial: 7482648
Drug: BY963 (spherosome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BY963 (spherosome suspension containing a phospholipid), administered in three doses (2.5, 5, and 10 mL) at four different injection rates (0.25, 0.5, and 1 mL/s and bolus)
Trial: 7482648
Drug: BY963 (spherosome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BY963 (spherosome suspension containing a phospholipid)
Trial: 30276532
Drug: PH1-Cons (under
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PH1-Cons (under conservative treatment)
Trial: 24976429
Drug: Aged black
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aged black garlic (ABG), 6 g/d, twice daily for 12 weeks
Trial: 17950791
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus planned glycoprotein IIb/IIIa inhibitor (GPI)
Trial: 16343666
Drug: Antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet therapy (Aspirin)
Trial: 16343666
Drug: Anticoagulant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant therapy (Warfarin)
Trial: 1389192
Drug: Lidocaine inhalation
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine inhalation 40 mg
Trial: 1389192
Drug: Lidocaine inhalation
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine inhalation 120 mg
Trial: 1389192
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) lidocaine 1 mg/kg
Trial: 1389192
Drug: Saline inhalation
RxNorm normalized name: Broncho Saline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline inhalation (placebo)
Trial: 25945935
Drug: Ultrasound-guided pulsed
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided pulsed radio frequency treatment
Trial: 24286801
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of cultured MSCs with hyaluronic acid 3 weeks after surgery
Trial: 1411403
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (tetracycline, ornidazole, bismuth subcitrate)
Trial: 3931154
Drug: Scopolamine (centrally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (centrally active anticholinergic drug) administered in three different intravenous doses
Trial: 19891620
Drug: Autologous stem
RxNorm normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous stem cell treatment for cardiac repair
Trial: 9391668
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (middle ear pressure changes)
Trial: 8430715
Drug: Immunologic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunologic therapy with dialyzable leukocyte extract
Trial: 8430715
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of immunologic therapy and CBT
Trial: 8430715
Drug: Nonspecific treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonspecific treatment regimens
Trial: 30798674
Drug: Treatment supporters
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment supporters providing medical and social support to PLWHA
Trial: 30798674
Drug: Open communication
RxNorm normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open communication and committed emotional support from treatment supporters
Trial: 30798674
Drug: Training and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training and systemic support for treatment supporters
Trial: 30798674
Drug: Lack of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lack of HIV-related knowledge among treatment supporters
Trial: 30115112
Drug: Home-based self-help
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based self-help metacognitive therapy (Home-MCT) plus usual cardiac rehabilitation
Trial: 24411003
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg plus ezetimibe
Trial: 20814815
Drug: Capecitabine plus
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine plus enzastaurin (1,250 mg/m² twice daily plus 500 mg/day)
Trial: 17551305
Drug: Docetaxel plus
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel plus gemcitabine (docetaxel 75 mg/m2 on day 8 and gemcitabine 1000 mg/m2 on day 1 and day 8 every 3 weeks for 6 cycles)
Trial: 15867552
Drug: Intralesional corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional corticosteroid injection (CSI)
Trial: 8726539
Drug: Cabergoline (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (up to 5 mg daily)
Trial: 8726539
Drug: Cabergoline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (10 mg daily in open-label phase)
Trial: 8726539
Drug: Cabergoline (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (higher doses)
Trial: 1762811
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of a mannitol solution containing 7.5 mg/kg L‐tryptophan
Trial: 1762811
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of a mannitol solution containing 15 mg/kg L‐tryptophan
Trial: 1762811
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of 5% mannitol solution i.v.
Trial: 6210867
Drug: Danazol 100
RxNorm normalized name: danazol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol 100 mg/day
Trial: 6210867
Drug: Danazol 400
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Danazol 400 mg/day
Trial: 6210867
Drug: Danazol (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (various doses)
Trial: 6210867
Drug: Danazol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (600 mg/day) with amenorrhea
Trial: 6210867
Drug: Post-treatment follow-up
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment follow-up in infertile patients
Trial: 25748293
Drug: Minodronic acid
RxNorm normalized name: Minodronic acid
DrugBank: Minodronic acid (DB06548)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Minodronic acid 1 mg (single dose)
Trial: 25748293
Drug: Minodronic acid
RxNorm normalized name: Minodronic acid
DrugBank: Minodronic acid (DB06548)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Minodronic acid 1 mg (repeated doses for 7 days)
Trial: 25748293
Drug: Minodronic acid
RxNorm normalized name: Minodronic acid
DrugBank: Minodronic acid (DB06548)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Minodronic acid 4 mg (single dose under fed conditions)
Trial: 25748293
Drug: Minodronic acid
RxNorm normalized name: Minodronic acid
DrugBank: Minodronic acid (DB06548)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Minodronic acid (various doses 1, 2, and 4 mg)
Trial: 25675570
Drug: Elongated needle
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elongated needle therapy at Tiantu (CV 22)
Trial: 25675570
Drug: Regular needle
RxNorm normalized name: CareOne 1ML 30G 1/2 inch Regular Needle Insulin Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular needle therapy at Tiantu (CV 22)
Trial: 17543140
Drug: Acetyl L-carnitine
RxNorm normalized name: Nature's Way Acetyl L-Carnitine Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl L-carnitine (LAC) 500 mg, 2 capsules/day plus 500 mg i.m. injection for 2 weeks, then 3 capsules/day for 8 weeks
Trial: 17543140
Drug: Placebo, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 2 capsules/day plus placebo i.m. injection for 2 weeks, then placebo for 8 weeks
Trial: 17543140
Drug: Acetyl L-carnitine
RxNorm normalized name: Nature's Way Acetyl L-Carnitine Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl L-carnitine (LAC)
Trial: 14749760
Drug: Mineral water
RxNorm normalized name: mineral water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineral water fortified with folic acid (563 microg/day), vitamins B(6) (1 mg/day), B(12) (7.5 microg/day), cholecalciferol (0.6 microg/day), and calcium (563 mg/day)
Trial: 1606348
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg intravenous ciprofloxacin
Trial: 1606348
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg intravenous ciprofloxacin
Trial: 4003485
Drug: Hypertonic solution
RxNorm normalized name: Hypertonic solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic solution (670 ml Osmol)
Trial: 4003485
Drug: Hypotonic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotonic solution (224 ml Osmol)
Trial: 28929521
Drug: Radavirsen 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radavirsen 0.5 mg kg-1 to 8 mg kg-1 (single ascending doses)
Trial: 28929521
Drug: Radavirsen 8
RxNorm normalized name: Radavirsen
DrugBank: Radavirsen (DB15332)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radavirsen 8 mg kg-1 (multiple doses)
Trial: 28929521
Drug: Placebo (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (single ascending doses)
Trial: 16446748
Drug: Tissue Monitoring
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue Monitoring System (TMS) - participants weighed themselves daily and received feedback on weight changes via email.
Trial: 16446748
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group - participants were weighed at the beginning and the end of the semester without daily monitoring.
Trial: 11005266
Drug: Cabergoline (CAB)
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline (CAB) 0.5 mg twice weekly
Trial: 11005266
Drug: Quinagolide (QUI)
DrugBank: Quinagolide (DB09097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinagolide (QUI) 75 microg once daily
Trial: 1287833
Drug: Procainamide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procainamide (25 mg/min, max dose 15 mg/kg)
Trial: 1287833
Drug: Digoxin (0.75-1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (0.75-1.0 mg intravenously according to renal function and body weight)
Trial: 29771807
Drug: Oral isotonic
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral isotonic glucose-sodium hydration solution for 40 days postdischarge
Trial: 26703919
Drug: Supplemental parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental parenteral nutrition strategy for 7 days post randomisation
Trial: 23557411
Drug: Octreotide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (100 μg subcutaneously every 8 h; n = 32)
Trial: 18549361
Drug: Continuous opioid
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous opioid therapy (COT)
Trial: 16389581
Drug: Vocational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vocational therapy approaches
Trial: 10698876
Drug: Six week
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six week domiciliary occupational therapy
Trial: 9098588
Drug: Mibefradil added
RxNorm normalized name: mibefradil
DrugBank: Mibefradil (DB01388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mibefradil added to standard therapy for heart failure
Trial: 3954110
Drug: Lidocaine plus
RxNorm normalized name: Icy Hot Lidocaine Plus Menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine plus 0.5 ml normal saline (Group 1)
Trial: 3954110
Drug: Lidocaine plus
RxNorm normalized name: Icy Hot Lidocaine Plus Menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine plus 0.3 mg epinephrine (Group 2)
Trial: 3954110
Drug: Lidocaine plus
RxNorm normalized name: Icy Hot Lidocaine Plus Menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine plus 5 mg phenylephrine (Group 3)
Trial: 20634355
Drug: Placebo (interspinous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (interspinous saline, L(3)-L(4))
Trial: 18155934
Drug: Exposure plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure plus usual treatment
Trial: 18155934
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list control plus usual treatment
Trial: 18155934
Drug: All patients
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients treated (pre to post-treatment)
Trial: 16177596
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g UWP/d
Trial: 12933391
Drug: 5% lidocaine-prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lidocaine-prilocaine (EMLA) cream
Trial: 14588914
Drug: Routine hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine hospital treatment and discharge instructions (control group)